LUCECO UK LIMITED
Company number 02255270 · Monitor this company
This analysis was written by an AI from the company's public filings. It may contain errors or omissions and is not financial or professional advice.
Financial Health Assessment — LUCECO UK LIMITED
Company number 02255270 · Wholesale of electrical household goods (SIC 46439) · Active
0. An important word on the evidence base (read this first)
A diagnosis is only as good as the tests available. For this assessment I have been given the patient's file cover, identity band and appointment record — but not the bloods. Specifically, the dataset contains: statutory identity and status, filing metadata, share capital, officers, persons with significant control (PSC), SIC code, name history and a website description. It does not contain any figures from the filed accounts — no turnover, gross margin, operating profit, debtors, stock, creditors, cash, net current assets, net assets or shareholders' funds.
I will not invent those numbers. Instead I will do three things: (1) score the vitals I can observe, (2) explain precisely what the missing vitals would tell us and what to look for, and (3) give a provisional diagnosis plus the specific data needed to convert it into a firm one. Everything below is stated on that basis, and any statements about the company's own filings are the company's stated position, not independently verified fact.
1. Financial Health Score
| Dimension | Grade | Basis |
|---|---|---|
| Filing & compliance vitality | A | Accounts and confirmation statement both current, neither overdue |
| Governance & ownership stability | B+ | Long-established, clear group ownership, one board change in the period |
| Transparency & disclosure quality | C | Filed as an audit-exemption subsidiary; limited-company accounts are typically filleted (no P&L, no audit report) |
| Solvency, liquidity & profitability | Not assessable (ND) | No financial figures in the dataset |
| OVERALL (provisional) | B — "stable but unexamined" | Strong structural signals, unverified financial condition |
How to read this grade. A "B" here is not a clean bill of health; it is a provisional score reflecting that the observable indicators are reassuring while the core financial vitals remain unmeasured. Think of a patient with excellent attendance at check-ups, a long unbroken history, a named corporate next-of-kin who has agreed to stand behind the bills — but whose test results nobody has looked at. The structural prognosis is good; the physiological one is unknown.
2. Key Vital Signs
2.1 Vitals observed
| Vital sign | Reading | What it indicates |
|---|---|---|
| Corporate age / longevity | Incorporated 10 May 1988 — 37+ years | The single most underrated health marker. Companies that survive four decades of cycles, multiple rebrands and a wholesale sector shakeout have demonstrated adaptive capacity. "Chronic" conditions are unlikely to be undiagnosed. |
| Filing pulse | Accounts made up to 31 Dec 2025; next due 30 Sep 2027. Confirmation statement current, next due 27 Oct 2027. Not overdue. | A regular, timely pulse. Late filing is one of the earliest observable symptoms of back-office strain, cash stress or board dysfunction. None present here. |
| Accounting reference date | 31 December | Aligned to the group's calendar-year reporting. Facilitates consolidation — a sign of integrated group reporting rather than a standalone bolt-on. |
| Ownership / "blood supply" | Luceco Holdings Limited holds >75% of shares and voting rights, and the right to appoint and remove directors. A second PSC entry records an individual with significant influence or control. | A wholly-owned operating subsidiary with a committed parent. In practice, the parent is the company's circulatory system: funding, treasury, guarantees and credit support flow from it. |
| Accounts category | Audit Exemption Subsidiary | This is the most diagnostically informative single data point. It means the company relies on the statutory subsidiary exemption (parent guarantee of liabilities, inclusion in group consolidated accounts) to avoid a standalone audit. Two implications: positive — explicit parental support (a form of financial "next-of-kin" guarantee); negative — weaker independent assurance and near-certainly no profit and loss account on the public file. |
| Capital structure | Issued share capital £1 | Nominal only — typical of a group operating subsidiary. The company is almost certainly funded by intra-group debt and trading balances, not equity. |
| Business activity | Wholesale of radio, TV and electrical household appliances | A distribution/wholesale model in a cyclical, discretionary-adjacent category tied to construction, refurbishment and retail demand. Wholesale margins are structurally thin; working capital (stock and receivables) is the balance-sheet battleground. |
| Board composition | Three current directors; a corporate secretary; one director resigned 15 June 2026. Directors include a German national, indicating group-level European oversight. | A functioning, plural board with independent administrative support. One departure in a reporting cycle is within normal turnover; it is a governance event, not a symptom. No reason for the resignation is given in the data. |
| Brand continuity | Masterpiece MBC Ltd (to 1993) → Masterplug Ltd (to 2012) → Nexus Industries Ltd (to 2019) → Luceco UK Ltd | A deliberate, staged integration into the parent's brand architecture. Name changes of this kind usually accompany group rationalisation of trading entities — often efficiency-positive. It does, however, complicate longitudinal comparison of filed data. |
| Trading identity | Website describes design, supply and manufacture of LED lighting for commercial and domestic use | A branded, specification-led proposition rather than pure commodity resale. Brand and specification typically support better gross margin than unbranded distribution — though this must be verified in the numbers. |
2.2 Vitals not observed — and why each matters
| Missing vital sign | The "symptom" it would reveal | Warning threshold to watch for |
|---|---|---|
| Turnover trend (3–5 yr) | Growth or contraction of the underlying franchise | Two consecutive years of decline |
| Gross margin % | Pricing power; input-cost and FX pass-through | Falling margin while turnover rises = buying volume |
| Operating profit / margin | Whether the distribution model actually earns | Sub-2% operating margin in wholesale = fragile |
| Net current assets (working capital) | Short-term survivability | Negative, or a sharp year-on-year fall |
| Current ratio / quick ratio | Ability to meet the next 12 months of obligations | Below 1.0, or a quick ratio below 0.7 with heavy stock |
| Stock days | Obsolescence risk (LED technology turns over quickly) | Rising stock days while sales fall = dead inventory |
| Debtor days | Credit control and customer concentration | Rising days = customers stretching, or distress in the customer base |
| Creditor days / intercompany balance | Whether the company is funded by the parent or funding the parent | A large debit (owed to the company by group) is a concealed liquidity risk |
| Interest cover | Debt-service resilience | Below 3x |
| Net assets / shareholders' funds | Cumulative profitability and balance-sheet integrity | Falling reserves = accumulated losses |
| Contingent liabilities / parent guarantee note | Whether the audit exemption rests on a valid, subsisting guarantee | Guarantee withdrawal would trigger an audit obligation |
| Dividend and impairment notes | Cash extraction versus reinvestment | Dividends exceeding post-tax profit |
3. Diagnosis
Primary diagnosis: a structurally sound, group-embedded operating subsidiary in satisfactory administrative health — with unverified financial physiology.
Four findings drive that conclusion.
Finding 1 — Healthy administrative constitution. Timely accounts and confirmation statement, an active company secretary, a multi-director board, and no overdue filings. In diagnostic terms, this is the equivalent of good tone, colour and hydration: non-specific but strongly correlated with competent management. Filing delinquency is often the first visible lesion; there is none.
Finding 2 — The company's financial health is, in substance, the group's financial health. With £1 of share capital and >75% ownership by Luceco Holdings Limited, the balance sheet will be dominated by intra-group funding and trading balances. Two consequences follow. First, the company's own net assets are a poor gauge of resilience: a parent can capitalise, lend or support at will, and the statutory balance sheet may look robust in one year and thin the next purely because of treasury decisions taken elsewhere. Second, the decisive question is not "is Luceco UK solvent?" but "is the parent willing and able to keep it solvent?" Under the audit exemption regime the parent must stand behind the subsidiary's liabilities — a meaningful signal of commitment, though it is a commitment of unknown financial capacity until group accounts are read.
Finding 3 — The transparency condition is the weak spot, not the financials. The "Audit Exemption Subsidiary" classification, combined with small-company filing rights, means the public record is likely to show a filleted balance sheet with no profit and loss account and no audit report. Stakeholders — credit insurers, landlords, large customers, suppliers considering extended terms — are therefore being asked to accept a diagnosis without sight of the most informative test results. This is the single greatest evidentiary weakness in the file. It is not evidence of ill health; it is evidence of unexamined health.
Finding 4 — The business model carries identifiable, sector-standard risks. Wholesale distribution of electrical and lighting products exposes the company to: cyclical construction and refurbishment demand; discretionary consumer spending; import cost and currency exposure (lighting supply chains are substantially Asian, so sterling weakness compresses margin quickly); technology obsolescence in stock; and customer concentration among electrical wholesalers and retailers. None of these is a present symptom — but they define which vitals must be monitored most closely, and they explain why a "thin but stable" margin profile would be the expected normal rather than a red flag in itself.
Differential to rule out (with data). The absence of figures means I cannot exclude: (a) an entity sustained by parent funding but loss-making on a standalone basis; (b) an entity with negative working capital funded by creditor stretch; (c) an entity carrying a large receivable from group companies that is, in economic substance, thinly disguised group financing. Any of these would move the provisional B down materially. Equally, a five-year record of stable margins, positive net current assets and no group receivable would move it to an A- on financial condition.
4. Prognosis
Short term (next 12 months): stable, contingent on group support. Filing obligations are comfortably met, with the next accounts due 30 September 2027 and confirmation statement due 27 October 2027. No administrative event threatens continuity. The board has three serving directors and a secretary, so there is no key-person vacuum on the public record.
Medium term (1–3 years): stable, conditional on three things. 1. Parent support remaining intact. The audit exemption and, more importantly, the company's funding model depend on it. The prognosis is only as good as the parent's balance sheet. 2. Sector demand. Wholesale electrical goods track construction, refurbishment and retail footfall. A downturn would show up first as rising debtor days and swelling stock, not as a fall in turnover. 3. Margin defence. Input-cost inflation and currency movement pass through this model with a lag. The tell-tale sign of strain will be gross margin erosion while turnover holds up.
Watch-items (early-warning symptoms to monitor): a shift from a net intercompany creditor to a net intercompany debtor position; a fall in net current assets between consecutive filings; any change to the audit-exemption basis or the parent guarantee; any further board departures clustered in time; and any late filing — the earliest observable symptom of strain.
Overall, the prognosis is favourable but unconfirmed: this reads like a long-standing, well-integrated trading subsidiary of a group that has invested in it repeatedly through four name changes and nearly four decades. That is a good patient history. It is not a diagnosis.
5. Recommendations
Clinical — obtain the missing test results (priority 1) 1. Pull the last three years of filed accounts from Companies House and extract: turnover, gross profit, operating profit, net current assets, total assets less current liabilities, net assets, and the intercompany debtor/creditor split. Three years gives trend, which matters more than any single year. 2. Read the notes, not the face of the balance sheet. Specifically the parent-guarantee note supporting the audit exemption, related-party transactions, contingent liabilities, and any secured borrowings. 3. Request management information if you have a legitimate interest (credit, supply, partnership): management accounts to the latest month, aged debtor and aged creditor listings, and a 13-week cash flow forecast. These are the equivalent of a live blood pressure reading where the filed accounts are a historical record.
Preventive — build a monitoring dashboard (priority 2)
Track these eight, monthly, for the company and compare against the prior year:
| Metric | Why it matters here | Red line |
|---|---|---|
| Gross margin % | Pricing power and FX pass-through | Two consecutive quarterly falls |
| Operating margin % | Whether the model earns | < 2% |
| Current ratio | Near-term survivability | < 1.0 |
| Quick ratio (excl. stock) | Survives without selling stock | < 0.7 |
| Stock days | LED obsolescence | Rising while sales flat/falling |
| Debtor days | Customer stress and concentration | > 60 days, or rising >10 days YoY |
| Net intercompany position | Is the company funder or funded? | Swing from creditor to debtor |
| Interest cover | Debt service resilience | < 3x |
Structural — improve the company's financial "immune response" (priority 3) 4. Formalise the parent support position. Ensure the guarantee underpinning the audit exemption is current and, where third parties rely on it, obtain a letter of support as a matter of routine rather than on request. This is the cheapest available credit enhancement. 5. Consider a voluntary audit or fuller reporting if the company bids for large contracts, seeks significant supplier credit, or is exposed to credit-insurance scrutiny. The cost is small relative to the friction of being an unexamined counterparty. 6. Manage the risk factors the model is exposed to: currency hedging for imported product (natural hedge or forward cover), credit insurance on receivables if customer concentration is material, and a documented stock-obsolescence policy with regular provisioning. 7. Reduce single-sector concentration through broadening the specification/project channel and the commercial (as opposed to residential) mix — the branded LED proposition described on the website supports this. 8. Document succession and delegation at board level. With one director having resigned in the period and a small board, clarity on delegated authority and financial controls protects continuity of the entity, not any individual.
What would change the diagnosis. If three years of figures show stable or rising gross margin, positive and improving net current assets, and no material group receivable, the provisional B should be upgraded to A-/A on financial condition. If they show negative working capital, a growing group debtor, or accumulated losses, the diagnosis becomes "stable only because it is supported" — a materially different and less comfortable position, and a signal to tighten credit terms with the company accordingly.